Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

NCT00624585 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Dasatinib

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]